[go: up one dir, main page]

DK3571193T3 - Potassium Channel Modulators - Google Patents

Potassium Channel Modulators Download PDF

Info

Publication number
DK3571193T3
DK3571193T3 DK18704122.3T DK18704122T DK3571193T3 DK 3571193 T3 DK3571193 T3 DK 3571193T3 DK 18704122 T DK18704122 T DK 18704122T DK 3571193 T3 DK3571193 T3 DK 3571193T3
Authority
DK
Denmark
Prior art keywords
potassium channel
channel modulators
modulators
potassium
channel
Prior art date
Application number
DK18704122.3T
Other languages
English (en)
Inventor
Dipak Vasantrao Amrutkar
Kelly Foster
Thomas Amos Jacobsen
Martin R Jefson
Gregg F Keaney
Janus Schreiber Larsen
Karin Sandager Nielsen
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Application granted granted Critical
Publication of DK3571193T3 publication Critical patent/DK3571193T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
DK18704122.3T 2017-01-23 2018-01-23 Potassium Channel Modulators DK3571193T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449270P 2017-01-23 2017-01-23
PCT/US2018/014792 WO2018136917A1 (en) 2017-01-23 2018-01-23 Potassium channel modulators

Publications (1)

Publication Number Publication Date
DK3571193T3 true DK3571193T3 (da) 2022-01-17

Family

ID=61188924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18704122.3T DK3571193T3 (da) 2017-01-23 2018-01-23 Potassium Channel Modulators

Country Status (30)

Country Link
US (4) US9975886B1 (da)
EP (1) EP3571193B1 (da)
JP (1) JP6997197B2 (da)
KR (1) KR102664772B1 (da)
CN (1) CN110198935B (da)
AR (1) AR110770A1 (da)
BR (1) BR112019014814B1 (da)
CL (1) CL2019002031A1 (da)
CO (1) CO2019009060A2 (da)
CU (1) CU24560B1 (da)
CY (1) CY1125463T1 (da)
DK (1) DK3571193T3 (da)
EA (1) EA036668B1 (da)
ES (1) ES2906078T3 (da)
HR (1) HRP20220079T1 (da)
HU (1) HUE057710T2 (da)
IL (1) IL267954B (da)
LT (1) LT3571193T (da)
MX (1) MX376080B (da)
MY (1) MY195123A (da)
PH (1) PH12019501678A1 (da)
PL (1) PL3571193T3 (da)
PT (1) PT3571193T (da)
RS (1) RS62899B1 (da)
SG (1) SG11201905893WA (da)
SI (1) SI3571193T1 (da)
TW (1) TWI751271B (da)
UA (1) UA123810C2 (da)
WO (1) WO2018136917A1 (da)
ZA (1) ZA201904458B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210545A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) * 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
WO2020086456A1 (en) * 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN118985622B (zh) * 2024-07-05 2025-12-02 云南大学 一种吡唑类化合物在防治植物根结线虫中的应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
GB2183243B (en) 1985-10-09 1990-01-24 Nippon Oil Co Ltd Process for preparing oil-soluble nitrogen-containing compounds
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
LU87304A1 (fr) 1988-07-29 1990-02-07 Oreal Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie
JPH02282251A (ja) 1989-04-24 1990-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4034762A1 (de) 1990-11-02 1992-05-07 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DK72693D0 (da) 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
AU3785597A (en) 1996-08-14 1998-03-06 Takeda Chemical Industries Ltd. Cyclic urea compounds, their production and use as herbicides
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
JPH11282132A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP2000072695A (ja) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd 環状化合物
JP2000075449A (ja) 1998-08-31 2000-03-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像方法
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
AU775102B2 (en) 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
JP2004501192A (ja) 2000-06-29 2004-01-15 ニューロサーチ、アクティーゼルスカブ Ｋｃｎｑカリウムチャネルモジュレーターとしての３−置換オキシインドール誘導体の使用方法
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
WO2002046172A2 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
CN100509794C (zh) 2001-01-16 2009-07-08 阿斯特拉曾尼卡有限公司 治疗性杂环化合物
KR20030070916A (ko) 2001-01-16 2003-09-02 아스트라제네카 아베 치료용 크로몬 화합물
BR0206514A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1432690A2 (en) * 2001-04-16 2004-06-30 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
JP2006500372A (ja) 2002-08-19 2006-01-05 グラクソ　グループ　リミテッド 選択的ｃｏｘ−２阻害物質としてのピリミジン誘導体
WO2004017920A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7589092B2 (en) 2003-06-20 2009-09-15 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
AU2004265341A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP4948173B2 (ja) 2003-10-10 2012-06-06 ニツポネツクス・インコーポレーテツド 過剰増殖性疾患治療用ピリミジン誘導体
MXPA06004191A (es) 2003-10-17 2007-01-19 Incyte Corp Hidroxamatos ciclicos sustituidos en la forma inhibidores de metaloproteinasas de matriz.
CA2545992A1 (en) 2003-11-24 2005-06-16 F. Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005095357A2 (en) 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JP4926943B2 (ja) 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2581623A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2008527028A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
WO2006077412A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
CA2594878A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
AU2005325497A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2006077367A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006097441A1 (en) 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
MX2008001428A (es) 2005-07-30 2008-04-04 Astrazeneca Ab Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
FR2892859B1 (fr) 2005-10-27 2008-06-06 Commissariat Energie Atomique Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
CA2633569A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
CA2633541A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
EP1999270A4 (en) 2006-03-13 2010-04-28 Perkinelmer Las Inc SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROSCOPY DETECTION
JP2009535370A (ja) 2006-05-02 2009-10-01 クリス ルントフェルト ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008016300A2 (en) 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
US20110144140A1 (en) 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
EP2074113A1 (en) 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
EP2121662A1 (en) 2006-12-04 2009-11-25 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
JP2010518107A (ja) 2007-02-06 2010-05-27 ノバルティス アーゲー Ｐｉ３−キナーゼ阻害剤およびその使用方法
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
BRPI0808746B8 (pt) 2007-03-28 2021-05-25 Neurosearch As derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila.
US8362024B2 (en) 2007-03-28 2013-01-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5111039B2 (ja) 2007-09-27 2012-12-26 富士フイルム株式会社 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
KR101102640B1 (ko) 2008-02-08 2012-01-04 가부시키가이샤 시세이도 미백제 및 피부 외용제
WO2009105881A1 (en) 2008-02-28 2009-09-03 Saint Mary's University Ionic liquids comprising ligands containing positively charged heterocyclic ring useful as catalyst and for metal extractions
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
US8642778B2 (en) 2008-05-28 2014-02-04 Merck Patent Gmbh Ionic liquids
BRPI0915101A2 (pt) 2008-06-11 2017-03-21 Astrazeneca Ab composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
CA2766033C (en) 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
EA026674B1 (ru) 2009-07-08 2017-05-31 Балтик Био Аб Соединения, применимые в качестве лекарственных средств
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
EP2499195B1 (en) 2009-11-13 2020-12-09 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
AT509266B1 (de) 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
PE20130576A1 (es) 2010-05-13 2013-05-19 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US20120046301A1 (en) 2010-08-20 2012-02-23 Gruenenthal Gmbh Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor
PL2609086T3 (pl) * 2010-08-27 2015-07-31 Gruenenthal Gmbh Podstawione 2-okso- i 2-tiookso-dihydrochinolino-3-karboksyamidy jako modulatory KCNQ2/3
TW201218480A (en) 2010-09-30 2012-05-01 Basf Se Additive for electrolytes
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
CN103298460B (zh) 2010-12-14 2016-06-01 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012109343A2 (en) 2011-02-08 2012-08-16 President And Fellows Of Harvard College Iron complexes and methods for polymerization
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
EP3552664A1 (en) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostasis regulators
TWI567084B (zh) 2011-05-31 2017-01-21 麥克專利有限公司 含有氫－三氰－硼酸根陰離子之化合物
EP2721027B1 (en) 2011-06-03 2017-05-31 Massachusetts Institute of Technology Z-selective ring-closing metathesis reactions
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
BR112014004832A2 (pt) 2011-08-29 2017-04-04 Ptc Therapeutics Inc compostos antibacterianos e métodos para uso
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
JP5857713B2 (ja) 2011-12-15 2016-02-10 コニカミノルタ株式会社 光学フィルム、偏光板、及び液晶表示装置
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
US20150197503A1 (en) 2012-07-27 2015-07-16 Bial-Portela & Cª, S.A. Process for the synthesis of substituted urea compounds
US20150246024A1 (en) 2012-08-20 2015-09-03 The University Of Chicago Methods and compositions for inhibiting gram positive bacteria
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
EP2897948B1 (en) 2012-09-18 2016-08-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
ES2469290B2 (es) 2012-12-17 2015-01-26 Ocupharm Diagnostics S.L. Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos
US9279094B2 (en) 2012-12-21 2016-03-08 Afton Chemical Corporation Friction modifiers for use in lubricating oil compositions
US9499762B2 (en) 2012-12-21 2016-11-22 Afton Chemical Corporation Additive compositions with a friction modifier and a detergent
EP2941423B1 (en) 2013-01-07 2021-06-09 University of Southern California Deoxyuridine triphosphatase inhibitors
WO2014108487A1 (en) 2013-01-10 2014-07-17 Universite D'aix-Marseille P-stereogenic chiral precursor of chiral ligands and use thereof
WO2014134141A1 (en) 2013-02-26 2014-09-04 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CA2908695A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
KR102167199B1 (ko) 2013-07-02 2020-10-19 메르크 파텐트 게엠베하 유기 전계발광 소자
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105611924A (zh) 2013-07-25 2016-05-25 泰莱托恩基金会 Fapp2的抑制剂及其用途
WO2015013715A2 (en) 2013-07-26 2015-01-29 Thr Regents Of The University Of California C-h fluorination of heterocycles with silver (ii) fluoride
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
SG11201602387RA (en) 2013-10-21 2016-05-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CN103626741A (zh) 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
RU2680070C1 (ru) 2013-11-29 2019-02-14 Проионик Гмбх Способ отверждения клея с помощью микроволнового облучения
US20160304466A1 (en) 2013-12-04 2016-10-20 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
HRP20190039T1 (hr) 2014-04-04 2019-03-08 Syros Pharmaceuticals, Inc. Inhibitori ciklin-ovisne kinaze 7 (cdk7)
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
GB201502412D0 (en) 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
US20170299609A1 (en) 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
WO2017210545A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
WO2018136918A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels

Also Published As

Publication number Publication date
HRP20220079T1 (hr) 2022-04-15
US10351553B2 (en) 2019-07-16
ZA201904458B (en) 2023-04-26
TWI751271B (zh) 2022-01-01
CU24560B1 (es) 2021-12-08
US20210380571A1 (en) 2021-12-09
IL267954A (en) 2019-09-26
WO2018136917A1 (en) 2018-07-26
IL267954B (en) 2022-02-01
CO2019009060A2 (es) 2019-08-30
BR112019014814A2 (pt) 2020-02-27
US20190352293A1 (en) 2019-11-21
LT3571193T (lt) 2022-02-10
EA036668B1 (ru) 2020-12-07
KR102664772B1 (ko) 2024-05-10
MX2019008682A (es) 2019-09-18
KR20190110572A (ko) 2019-09-30
ES2906078T3 (es) 2022-04-13
EA201991488A1 (ru) 2019-12-30
RS62899B1 (sr) 2022-03-31
EP3571193B1 (en) 2021-12-01
BR112019014814B1 (pt) 2024-03-12
US20180215746A1 (en) 2018-08-02
PL3571193T3 (pl) 2022-04-25
AR110770A1 (es) 2019-05-02
SI3571193T1 (sl) 2022-04-29
CU20190066A7 (es) 2020-03-04
CY1125463T1 (el) 2024-02-16
PT3571193T (pt) 2022-03-25
MX376080B (es) 2025-03-07
JP6997197B2 (ja) 2022-01-17
TW201838985A (zh) 2018-11-01
US9975886B1 (en) 2018-05-22
CN110198935A (zh) 2019-09-03
HUE057710T2 (hu) 2022-05-28
JP2020504165A (ja) 2020-02-06
CN110198935B (zh) 2022-05-31
CL2019002031A1 (es) 2019-10-04
EP3571193A1 (en) 2019-11-27
MY195123A (en) 2023-01-11
SG11201905893WA (en) 2019-08-27
PH12019501678A1 (en) 2020-06-01
US10717728B2 (en) 2020-07-21
UA123810C2 (uk) 2021-06-02

Similar Documents

Publication Publication Date Title
MA50014A (fr) Modulateurs de k-ras
DK3743406T3 (da) Tmem16a modulatorer
EP3183346C0 (en) CHANNEL MODULATORS
MA53943A (fr) Modulateurs de ror-gamma
MA55328A (fr) Modulateurs de ror-gamma
EP3684368A4 (en) SELECTIVE P2X3 MODULATORS
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3428388A4 (en) TUNNEL DRILL
HUE062866T2 (hu) TREX-1 modulátorok
DK3710726T3 (da) Transmission
DK3351526T3 (da) Diisopentylterephthalat
DK3488158T3 (da) Kanalpanel
EP3532062A4 (en) ROR GAMMA MODULATORS
EP3728590C0 (en) NEW THIOPHOSPHORAMIDITES
EP3704466A4 (en) ANALYTE DETECTION PROCESS
IL267954B (en) potassium channel modulators
EP3698005A4 (en) POST CLEARERS
DK3453806T3 (da) Tætningselement
FR3050757B1 (fr) Tunnelier
EP3854876A4 (en) MODIFIED CHANNEL RHODOPSIN
EP3521070A4 (en) ÉMETTTEUR
DK3391733T3 (da) Ballepresse
EP3501859A4 (en) Transmitter
DK3176515T3 (da) Kanalsamling